- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03993509
Effect of rTMS on Anxiety
September 5, 2023 updated by: University of Pennsylvania
Examining the Mechanisms of Anxiety Regulation Using a Novel, Sham-controlled, fMRI-guided rTMS Protocol and a Translational Laboratory Model of Anxiety
Given the overall lack of treatment adherence/efficacy, side effects of drugs, and the substantial burden of anxiety disorders on the individual and on the national healthcare system, there is a critical need for mechanistic research into the CNS mechanisms that underlie these disorders.
Accordingly, the objective of this grant is to use noninvasive neuromodulation to causally identify the key neural mechanisms that mediate the cognitive symptoms of anxiety.
This project is relevant to public health because it has the potential to lead to novel repetitive transcranial magnetic stimulation treatments for pathological anxiety.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Although extensive research has explored the involvement of subcortical structures in arousal, arousal symptoms are only one facet of the symptom profile shared across anxiety disorders.
Much less is known about the cognitive symptoms (i.e.
difficulty concentrating) experienced by anxiety patients.
Accordingly, there is a critical need for mechanistic research into the CNS mechanisms that mediate the cognitive symptoms experienced by anxiety patients.
Without such research, treatment development for these disorders will continue to make slow progress.
The objective of this application is to determine the key neural mechanisms that mediate the cognitive symptoms of anxiety.
The central hypothesis is that the right dorsolateral prefrontal cortex (dlPFC) regulates emotion through top-down inhibition of emotion-related regions.
The approach will be to use repetitive transcranial magnetic stimulation (rTMS) to study the effect of right dlPFC activity on objective and subjective measures of induced anxiety, anxiety-related working memory deficits (WM), and TMS-evoked blood oxygenation-level dependent (BOLD) responses during simultaneous TMS/fMRI (i.e.
target engagement).
The rationale for this approach is that by experimentally manipulating right dlPFC activity using rTMS, this research will be able to causally demonstrate involvement of this region in anxiety regulation, which could translate to future targeted rTMS treatments for anxiety.
The first aim will be to determine the effect of a 1-week course of rTMS treatment (1 Hz vs. 10 Hz; right dlPFC target) on anxiety using the threat of unpredictable shock paradigm.
The second aim will be to determine the effect of a 1-week course of rTMS treatment (1 Hz vs. 10 Hz; right dlPFC target) on anxiety-related WM-deficits using the Sternberg WM paradigm during threat of shock.
The third aim will be to demonstrate target engagement by measuring BOLD responses evoked by TMS pulses to the right dlPFC during threat of shock.
The work is innovative because it will combine advanced neuromodulatory techniques (fMRI guidance, electric-field modelling, neuronavigation, active-sham control) with a translational threat of shock paradigm.
PUBLIC HEALTH RELEVANCE: Once completed, this research should yield direct evidence for a causal role of the right dlPFC in anxiety regulation, complete with evidence of target engagement, and a novel application to anxiety.
Study Type
Interventional
Enrollment (Estimated)
63
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nicholas l Balderston, PhD
- Phone Number: 215-746-3085
- Email: nicholas.balderston@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Subjects must be 18-50 years old
- Able to give their consent
- Right-handed
Exclusion Criteria:
- Non-english speaking
- Any significant medical or neurological problems
- Current or past Axis I psychiatric disorder(s), active or history of active suicidal ideation
- Alcohol/drug problems in the past year or lifetime alcohol or drug dependence
- Medications that act on the central nervous system
- History of seizure
- History of epilepsy
- Increased risk of seizure for any reason
- Pregnancy, or positive pregnancy test
- IQ <80
- Any medical condition that increases risk for fMRI or TMS
- Any metal in their body which would make having an MRI scan unsafe
- Any sort of medical implants
- Hearing loss
- Claustrophobia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 Hz Arm
Subjects will receive a continuous train of 1 Hz stimulation until all 3000 pulses are delivered.
Consistent with the 10 Hz condition, TMS will occur during the Sternberg WM paradigm.
|
A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used.
The TMS coil will be placed on the head over the target.
rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model.
Subjects will receive 3000 pulses/session.
|
Experimental: 10 Hz Arm
Subjects will receive 75, 4 second trains at 10 Hz, separated by a 36 second ITI.
Stimulation will occur while subjects are doing the Sternberg WM paradigm.
The timing of the Sternberg task will be jittered so that each rTMS train will be administered during the maintenance interval of a WM trial.
|
A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used.
The TMS coil will be placed on the head over the target.
rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model.
Subjects will receive 3000 pulses/session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anxiety Potentiated Startle during NPU
Time Frame: 24 Hours
|
NPU Task: The instructed fear paradigm that will be implemented uses administration of predictable and unpredictable shocks to generate phasic and sustained forms of potentiated startle.
The experiment consists of three different conditions: no shock (N), predictable shock (P), and unpredictable shock (U), each lasting approximately 150 sec.
In the N condition, no shocks will be delivered.
In the P condition, shocks will be administered predictably, that is, only in the presence of a threat cue.
In the U condition, the shocks will be unpredictable.
In each 150-sec condition, an 8-sec cue will be presented four times.
The cue will signal the possibility of receiving a shock only in the P condition.
Startle probes will be presented either during the cue period, or the ITI.
|
24 Hours
|
Fear Potentiated Startle during NPU
Time Frame: 24 hours
|
NPU Task: The instructed fear paradigm that will be implemented uses administration of predictable and unpredictable shocks to generate phasic and sustained forms of potentiated startle.
The experiment consists of three different conditions: no shock (N), predictable shock (P), and unpredictable shock (U), each lasting approximately 150 sec.
In the N condition, no shocks will be delivered.
In the P condition, shocks will be administered predictably, that is, only in the presence of a threat cue.
In the U condition, the shocks will be unpredictable.
In each 150-sec condition, an 8-sec cue will be presented four times.
The cue will signal the possibility of receiving a shock only in the P condition.
Startle probes will be presented either during the cue period, or the ITI.
|
24 hours
|
Sternberg WM accuracy
Time Frame: 24 hours
|
Sternberg task: On each WM trial, subjects will see a series of 4 letters presented singularly (encoding period) that will be followed by a brief interval where subjects are required to maintain these letters (maintenance period).
At the end of the maintenance period, subjects will be prompted to make a response based on the task instructions (response period).
The response prompt will consist of a letter and a number.
The letter will be chosen from the study series, and the number will correspond to a position in the series.
The subjects will indicate whether the position of the letter in the series matches the number.
|
24 hours
|
TMS-evoked BOLD responses
Time Frame: 2 seconds (i.e. Latency of BOLD response)
|
As with Experiment 1, subjects will have Neutral, Predictable, and Unpredictable periods.
During the neutral periods, they will be safe from shocks.
During the predictable periods, they can receive shocks but only when there is a cue present.
During the unpredictable periods, they will be at risk for shock during the entire duration of the block.
Rather than probing their ongoing fear and anxiety with the startle probes, we will replace the startle probes with single TMS pulses to the right dlPFC.
This will allow us to causally examine the effect of right dlPFC activity (induced by the TMS pulse) on the neural activity that mediates fear (during the predictable cue) and anxiety (during the unpredictable cue and ITI).
Importantly, by replacing the startle probes with TMS pulses, it will be possible to directly compare the TMS-evoked BOLD responses to the pattern of startle responses collected during the MRI/pre-stimulation visit.
|
2 seconds (i.e. Latency of BOLD response)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 30, 2019
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
June 18, 2019
First Submitted That Met QC Criteria
June 19, 2019
First Posted (Actual)
June 20, 2019
Study Record Updates
Last Update Posted (Actual)
September 7, 2023
Last Update Submitted That Met QC Criteria
September 5, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 833320
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on rTMS to the right dlPFC
-
Samsung Medical CenterCompletedPost-stroke Cognitive ImpairmentKorea, Republic of
-
Samsung Medical CenterCompletedMild Cognitive ImpairmentKorea, Republic of
-
Wake Forest University Health SciencesTerminatedHealthy | Chronic Pain | Opioid Use | Pain, ChronicUnited States
-
University of CalgaryDefence Research and Development CanadaCompletedBrain Injuries | Transcranial Magnetic Stimulation | Stress Disorders, Post-Traumatic | Biomarkers | Depression, Anxiety | Magnetic Resonance SpectroscopyCanada
-
Jakub AntczakAndrzej Frycz Modrzewski Krakow UniversityNot yet recruitingBipolar Disorder | Unipolar DepressionPoland
-
Wake Forest University Health SciencesVirginia Tech Carilion School of Medicine and Research InstituteCompletedSmoking | Smoking Cessation | Addiction | Nicotine Dependence | Craving | Addiction Nicotine | Cigarette SmokingUnited States
-
United States Naval Medical Center, San DiegoCompletedPTSD, Post Traumatic Stress DisorderUnited States
-
Taipei Veterans General Hospital, TaiwanUnknownTreatment Resistant DepressionTaiwan
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Recruiting
-
Rutgers, The State University of New JerseyRecruiting